



2602 S. 24th Street . Phoenix, AZ 85034
Tel 602 759 1245 www.CyrexLabs.com

PRACTITIONER

DEMODR, DEMODR TEST

5040 N. 15th Avenue
Suite 307
Phoenix, Arizona 85015

PATIENT

Name: SAMPLE, REPORT

DOB:

Gender:

ACCESSION #:
REQUISITION #:
SAMPLE TYPE: Whole Blood
DOCTOR / PATIENT ID:
DATE COLLECTED:
DATE RECEIVED:
DATE OF REPORT:

| TEST | RESULTS | | | | |
|---|---------|----------|------|-----------------|----------|
| | Low | In-range | High | Reference Range | Units |
| The Lymphocyte MAP Comprehensive Lymphocyte Immunophenotyping | | | | | |
| Total WBC | | 6531 | | 4000-11000 | Cells/uL |
| Total Lymphocyte | | 2701 | | 1000-4000 | Cells/uL |
| % Lymphocyte | | | 41.4 | 20.0-40.0 | % |
| Total T Cell | | | 1862 | 440-1600 | Cells/uL |
| % T Cell | | 68.9 | | 46.0-82.0 | % |
| Total B Cell | | | 499 | 90-400 | Cells/uL |
| % B Cell | | 18.5 | | 6.0-18.0 | % |
| T Cell/B Cell Ratio | 3.7 | | | 4.0-11.0 | Ratio |
| Total T-Helper (CD4) Cell | | | 1133 | 500-1100 | Cells/uL |
| % T-Helper (CD4) Cell | | 41.9 | | 28.0-55.0 | % |
| Total Cytotoxic (CD8) T Cell | | | 705 | 200-500 | Cells/uL |
| % Cytotoxic (CD8) T Cell | | 26.1 | | 10.0-30.0 | % |
| CD4/CD8 Ratio | | 1.6 | | 1.0-4.0 | Ratio |
| Total T-Helper-1 Cell | | | 699 | 150-530 | Cells/uL |
| % T-Helper-1 Cell | | 25.9 | | 18.0-34.0 | % |
| Total T-Helper-2 Cell | | | 148 | 39-120 | Cells/uL |
| % T-Helper-2 Cell | | 5.5 | | 3.2-6.6 | % |
| TH1/TH2 Ratio | | 4.7 | | 1.0-5.0 | Ratio |
| Total T-Helper-17 (Th17) | | | 114 | 35-80 | Cells/uL |
| % T-Helper-17 | | 4.2 | | 2.5-6.2 | % |
| Total Regulatory T Cell (Treg) | | 38 | | 15-45 | Cells/uL |
| % Regulatory T Cell | 1.4 | | | 1.8-3.3 | % |
| Th17/Treg Ratio | | 3.0 | | 1.0-3.0 | Ratio |
| Total NK Cell (CD56+) | | | >400 | 60-220 | Cells/uL |
| % NK Cell (CD56+) | | 15.0 | | 3.0-15.0 | % |
| Total Cytotoxic NK cells (CD16+) | | | >291 | 30-200 | Cells/uL |
| % Cytotoxic NK cells (CD16+) | | | 11.6 | 2.0-10.0 | % |
| Total NKT (CD56+ CD16+ T Cell) | | 104 | | 10.0-120.0 | Cells/uL |
| % NKT (CD56+ CD16+ T Cell) | | 3.9 | | 1.0-6.0 | % |
| Total CD3- CD57+ Lymphocyte | | | 198 | 45.0-144.0 | Cells/uL |
| % CD3- CD57+ Lymphocyte | | | 7.3 | 1.6-6.2 | % |
| Total CD57+ CD8+ T Cell | | 179 | | 98.0-328.0 | Cells/uL |
| % CD57+ CD8+ T Cell | 6.6 | | | 9.2-16.6 | % |
| Total CD57+ CD16+ NK Cell | | | 168 | 35.0-133.0 | Cells/uL |
| % CD57+ CD16+ NK Cell | | 6.2 | | 2.0-7.4 | % |

*A: **Alert value.** Alert value(s) identified which exceeds established limits (high or low) to a degree that may constitute an immediate health risk to the individual or require immediate action on the part of the ordering physician. Cyrex Laboratories' Clinical Consultants are available to discuss by calling (602) 759-1245 to schedule an appointment.

< > symbols are shown when the result is beyond the reportable range. The number shown after symbol represents the minimum or maximum reportable measurement respectively.

Gopal Krishnan, PhD, Laboratory Director

Cyrex Laboratories is certified under the Clinical Laboratory Improvement Amendments of 1988 ("CLIA") as qualified to perform high-complexity clinical testing. Test result data on its own does not constitute a diagnosis of any disease. Only a physician or qualified healthcare professional should interpret the significance of a clinical lab test or make a diagnosis. This test was developed and its performance characteristics determined by Cyrex Laboratories, LLC. This test is a "lab developed test" and therefore not subject to clearance or approval by the US Food and Drug Administration. The names and titles of tests and arrays are for reference purposes only.